Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Computing
Conference & Expo
November 2-4, 2009 NYC
Register Today and SAVE !..

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
In many cases, the end of the year gives you time to step back and take stock of the last 12 months. This is when many of us take a hard look at what worked and what did not, complete performance reviews, and formulate plans for the coming year. For me, it is all of those things plus a time when I u...
SYS-CON.TV
ProNAi Expands Management Team and Presents Encouraging Phase I Study Results for Lead Cancer Drug at Cancer Meeting

PLYMOUTH, Mich., Nov. 9, 2012 /PRNewswire-USNewswire/ -- ProNAi Therapeutics, Inc., a private DNAi cancer drug development company, recently concluded its initial human clinical trial of PNT2258, a first-in-class, nucleic acid drug.  It is presenting the results of the Phase I study of PNT2258, an anti-Bcl-2 cancer drug, at the annual EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, a conference hosted by the European Organization for Research and Treatment of Cancer, the National Cancer Institute and the American Association for Cancer Research.

The company also expanded its management team with the recent appointments of board member and venture capital investor Mina Sooch, MBA, as President and CEO, and Dr. Richard Messmann, M.D., as Chief Medical Officer.

"The encouraging clinical results from our 22 patient study, conducted at START in Texas, showed we can achieve exposure levels in humans that were many times the level needed to achieve anti-tumor effect in animals without significant liver or blood platelet toxicity.  We also demonstrated statistically significant, dose-dependent, and specific knockdown of the Bcl-2 gene with suppression of protein levels up to 60 percent," said Dr. Messmann.  "Patients received the drug for extended periods of time without having material side effects seen with other anti-Bcl-2 drugs or nucleic acid cancer drugs in development.  These results indicate that we can administer the drug either as a single agent or potentially in combination with other anti-cancer drugs without adding patient side effects."

"PNT2258 represents the first of many targeted drugs in ProNAi's portfolio that utilize its emerging DNA interference platform called DNAi," added Sooch.  "We look forward to rapidly expanding PNT2258's clinical development to confirm efficacy in patients with Bcl-2-driven tumors, such as diffuse large B-cell lymphoma, follicular lymphoma and chronic lymphocytic leukemia.  We also anticipate eventual development into other solid tumors such as cancers of the lung, head and neck, and sarcomas.  ProNAi continues to pursue both venture capital funding and partnerships with pharmaceutical companies to advance these promising potential therapies for cancer.  ProNAi is proud to be a pioneer in nucleic acid therapeutics by overcoming the drug delivery challenges of RNA and DNA based therapies as it has demonstrated safe and effective systemic delivery beyond the liver in humans."

Prior to joining ProNAi, Mina Sooch, who has more than 20 years of experience in pharmaceuticals, healthcare, and M&A after receiving her MBA from Harvard University, helped co-found Apjohn Ventures Fund and several biotech start-ups.  Dr. Messmann, who has over 20 years extensive clinical experience as a medical oncologist and drug-development physician, recently served as Vice President of Medical Affairs for Endocyte [ECYT] where he led the development of vintafolide for ovarian cancer through successful late stage clinical trials.  The executive management team is rounded out by Dr. Wendi Rodrigueza, Chief Scientific Officer (formerly Novartis, Curagen, and Esperion), and ProNAi scientific advisors, led by Dr. Bruce Zetter of Harvard Medical School.

About PNT2258
PNT2258 is a 24-mer, single stranded, chemically unmodified (i.e., native) DNA oligonucleotide sequence called PNT100 encapsulated in a specialized anionic and pH "tunable" liposome.  PNT2258, which is delivered via a 2 hour infusion, has a long half-life of several days allowing it to infiltrate cancer cells, release into the nucleus, and initiate apoptosis by silencing the Bcl-2 target gene.

About ProNAi
ProNAi Therapeutics Inc. is a venture backed biotechnology company based in Plymouth and Kalamazoo, Michigan.  The novel DNAi drug platform is proprietary to ProNAi.  Unlike many RNA products (antisense, RNAi, microRNA, etc) that work in the cytoplasm of a cell, DNAi drugs are designed to target sequences that reside in the non-coding regions of the genome and block transcription in the nucleus, thereby silencing the gene of interest at the source.  DNAi therapeutics have the potential to treat cancer and other genetic diseases with an innovative and targeted approach.

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995.  These statements are based on management's current expectations and involve significant risks and uncertainties that may cause results to differ materially from those set forth in the statements.

Contact:
Mina Sooch
CEO, ProNAi
248-681-9815
msooch@pronai.com
www.pronai.com

SOURCE ProNAi Therapeutics, Inc.

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

SOA World Latest Stories
I've been writing recently about the dimensions of Big Data in the IoT: urgency, importance, frequency, consequences, remedy, cost. You can find my stories on IoT Journal or at my personal website. The big item missing from this list is, of course, size. How big are individual messa...
Processes are not documented and reused by a set of individuals because they lead to failure. Like design patterns, they are documented and reused because they lead to success. They are all put together by very talented people who have successfully used them to develop software multip...
Many mid-market companies have invested significant time and resources to secure and back up their servers, client computers, data, and overall network infrastructure in what was the traditional client-server setup. Now, what were considered emerging technologies just a few years ago, ...
Vormetric on Tuesday announced that Rackspace Hosting has joined the Cloud Partner program, and will be offering encryption and key management services to customers via Vormetric's Transparent Encryption solution. Vormetric's Transparent Encryption combines the performance, flexibility...
I'm reading a McKinsey report from May 2013 that talks about 12 disruptive technologies, including cloud computing and the Internet of Things (IoT). I'll focus on the IoT here. The report estimates the IoT Internet to be worth between $2.7 and $6.2 trillion by the year 2025.(The world'...
up.time, from uptime software, monitors performance, availability and capacity across all servers, virtual machines, applications, IT services, and the network. Proactively find IT system performance issues before they happen, report on total capacity, easily identify troublemakers, tr...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021


SYS-CON Featured Whitepapers
ADS BY GOOGLE